Telix Pharmaceuticals Ltd. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Telix Pharmaceuticals Ltd. (TLX).

If you purchased or held Telix Pharmaceuticals securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Telix Pharmaceuticals

Telix Pharmaceuticals is a biotechnology company focused on the development and commercialization of diagnostic and therapeutic products, particularly in the field of oncology. The company’s primary emphasis is on radiopharmaceuticals for cancer detection and treatment, with a notable focus on prostate cancer therapies.

The company’s lead product candidates include TLX591 and TLX592, both of which are being developed for the treatment of prostate cancer. Telix Pharmaceuticals has also reported progress in expanding its clinical trial programs and has highlighted the launch of its PSMA-imaging agent, Illuccix, for prostate PET imaging. The company is listed on both the Australian Securities Exchange (ASX) and Nasdaq.

Potential Concerns Under Investigation

Lawyers are investigating potential issues related to Telix Pharmaceuticals’ disclosures about its prostate cancer drug programs, especially in light of a recent regulatory development. On July 22, 2025, Telix Pharmaceuticals disclosed that it had received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking documents and information primarily related to the company’s disclosures regarding the development of its prostate cancer therapeutic candidates. This public admission of an SEC probe served as a key “corrective disclosure.”

The market reacted sharply to this news. On July 23, 2025, the next trading day, Telix Pharmaceuticals’ American Depository Shares (ADS) dropped about 10.3%, falling from approximately $16.28 to around $14.60. Refinitiv and Reuters reported that Telix shares tumbled as much as 16.4% intraday to multi-month lows on the ASX, finishing down approximately 12.4% for the day.

Legal professionals may examine whether Telix Pharmaceuticals made misleading statements or failed to adequately disclose material information about its prostate cancer programs. For example, the company repeatedly promoted its lead therapy TLX591, citing favorable Phase II data and promising timelines for clinical trial milestones. If internal data contradicted these public statements, lawyers may investigate whether such representations were false or misleading.

The Q2 2025 press release also included statements about clinical trial progress, such as having “consented all 30 patients required to complete Part 1” of the ProstACT trial and that the trial was “proceeding seamlessly into Part 2”. Attorneys could investigate if these statements accurately reflected the real status of the clinical program or if there were undisclosed enrollment or safety issues.

Beyond TLX591, Telix Pharmaceuticals made positive statements about other prostate cancer candidates and the expansion of its clinical programs. Lawyers may review whether these disclosures were complete and accurate or if any material information was omitted.

The investigation may also focus on the actions and knowledge of key executives, including CEO Christian Behrenbruch and CFO Darren Smith, who were involved in making public statements and signing regulatory filings. Legal professionals could examine whether these individuals acted knowingly or recklessly in connection with the company’s disclosures.

The SEC subpoena itself is a significant red flag and may indicate the presence of serious regulatory concerns regarding Telix Pharmaceuticals’ disclosures. The investigation may further consider the company’s motives to maintain a high stock price, such as recent fundraising and acquisitions, which could have benefited from positive news about its drug pipeline.

Your Rights and Next Steps

If you purchased or held Telix Pharmaceuticals securities between Jan. 13, 2025 and July 22, 2025 and suffered losses, you may have important legal rights. This is currently an investigation, not a filed lawsuit. However, if sufficient evidence is found, it may lead to a securities class action on behalf of affected investors.

Lawyers are ready to help investors understand their options and determine if they may be eligible to participate in a potential class action. Investors who join the investigation may have the opportunity to seek compensation for losses suffered as a result of any potential securities law violations.

It is important to act quickly, as securities investigations are time-sensitive and may be subject to strict deadlines. Investors should gather records of their Telix Pharmaceuticals purchases, sales, and holdings during the proposed class period and be prepared to provide information about their losses.

You May Be Entitled to Compensation

Investors who purchased Telix Pharmaceuticals securities and suffered financial losses may be eligible to join any potential class action and seek compensation. Time is of the essence, as securities investigations can move quickly and deadlines may apply.

To find out if you qualify and to take the next step, complete the form below to join the investigation.